- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Boehringer Ingelheim launches two initiatives to help those living with IPF
29 February 2016 • Author: Victoria White
To mark Rare Disease Day 2016, Boehringer Ingelheim has brought together patients, patient groups and globally renowned clinicians to launch a report into idiopathic pulmonary fibrosis (IPF) entitled Inspiration.
The new initiative is dedicated to raising awareness of IPF, a rare disease that is relatively unheard of, frequently misdiagnosed and little understood.
Here in the UK, more than 15,000 people have IPF. Currently, the average time to diagnosis is one to two years following the onset of symptoms, and the majority of patients will not live more than three years from diagnosis.
Professor Luca Richeldi, University of Southampton, commented: “With the number of people being diagnosed with IPF in the UK steadily increasing year on year, government and policymakers need to prioritise this condition as though it were a cancer. This report will go a long way towards achieving this aim.”
Survey reveals real-life emotions faced by those living with IPF
Mirroring the themes identified in this publication, an international survey of over 500 people living with IPF in more than 20 countries worldwide reveals the real-life emotions faced by those with the devastating disease. The results are launched on Rare Disease Day 2016 to coincide with this year’s theme ‘Patient Voice’, recognising the crucial role that patients play in voicing their needs.
When asked ‘what do you think of when you think of IPF?’, the thought most frequently expressed by respondents was breathlessness, one of the most common symptoms of IPF. As the condition causes the lung tissue to become thickened, stiff and scarred over time, the reality is that shortness of breath makes it difficult for people affected by IPF to carry out everyday tasks such as showering or getting dressed.5
The research also reveals that the progressive and unpredictable nature of this fatal lung disease places an emotional burden on those affected by the condition; almost a quarter of respondents said they fear not being able to do the things they used to do before having IPF and one in three people said they feel “frustrated” by the condition.
Dr Toby Maher, Consultant Respiratory Physician at the Royal Brompton Hospital, commented: “This thought-provoking research echoes what my patients talk to me about when we discuss life with IPF. Thankfully our understanding of the treatment of IPF has moved forward a lot in the last few years. As physicians we can help address the negative emotions many patients experience at diagnosis and improve how they see their future with the disease so they feel positive about starting effective treatment.”
Patient advocacy groups also play an extremely important role in making it easier to live with the condition; 42% of respondents said that patient groups made them feel less isolated and provide access to important information.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics